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Abstract
Background
Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A
meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the
leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epi-
demiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conju-
gate vaccine (PCV13) introduction in the pediatric routine immunization program in October
2013.
Methods
Nationwide population-based meningitis surveillance collects case-level demographic and
clinical information and cerebrospinal fluid (CSF) laboratory results. Sp infections are con-
firmed by culture, real-time polymerase chain reaction (rt-PCR), or latex agglutination, and
CSF serotyped using real-time and conventional PCR. We calculated incidence rates in
cases per 100,000 persons, adjusting for age and proportion of cases with CSF tested at
national reference laboratories, and case fatality ratios (CFR).
Results
During 2011–2013, 1,528 pneumococcal meningitis cases were reported. Average annual
adjusted incidence rates were 26.9 (<1 year), 5.4 (1–4 years), 7.2 (5–14 years), and 3.0
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(15 years). Overall CFR was 23% and highest among children aged <1 year (32%) and
adults30 years (30%). Of 1,528 cases, 1,036 (68%) were serotyped: 71% were PCV13-
associated serotypes, 14% were non-PCV13-associated serotypes, and 15% were non-
typeable by PCR. Serotypes 1 (45%) and 12F/12A/12B/44/46 (8%) were most common.
Among children aged <1 year, serotypes 5 (15%), 6A/6B (13%) and 1 (12%) predominated.
Conclusions
In Burkina Faso, the highest morbidity and mortality due to pneumococcal meningitis
occurred among children aged <1 year. The majority of cases were due to PCV13-associ-
ated serotypes; introduction of PCV13 should substantially decrease this burden.
Introduction
Infection with Streptococcus pneumoniae is one of the leading bacterial causes of morbidity
and mortality worldwide and includes life-threatening presentations such as meningitis, pneu-
monia and sepsis [1, 2]. S. pneumoniae is one of the primary etiologies of acute bacterial men-
ingitis, along with Neisseria meningitidis and Haemophilus influenzae type b (Hib) [3]. In the
meningitis belt of sub-Saharan Africa, stretching from Senegal to Ethiopia and including 430
million people in 26 countries [4], pneumococcal meningitis epidemiology is characterized by
relatively high incidence in all age groups, high case fatality, a predominance of serotype 1
after the first five years of life, and a seasonality more typically associated with meningococcal
meningitis [5–9].
Burkina Faso, a landlocked West African country with a population of approximately 19
million, is entirely located within the meningitis belt and experiences hyper-endemic rates of
meningitis [10, 11]. Historically, about 90% of meningitis cases during epidemics in Burkina
Faso were caused by N. meningitidis serogroup A [11] and, more recently by N. meningitidis
serogroup W [5, 12]. Prior to the introduction of the serogroup A meningococcal conjugate
vaccine (MenAfriVac) in 2010, national bacterial meningitis surveillance was strengthened [4,
13] through improvements in specimen collection, laboratory confirmation of bacterial etiolo-
gies, data transmission, and data management. Following the successful introduction of Hib
vaccine in 2006 [14] and MenAfriVac in 2010 [4], S. pneumoniae became the primary cause of
bacterial meningitis. On October 31, 2013, the government of Burkina Faso introduced the
13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization
program, to be administered to children at 8, 12, and 16 weeks of age.
Through the improved meningitis surveillance system and further expansion of national
capacity to confirm and serotype or serogroup all major bacterial etiologies of meningitis,
including S. pneumoniae [4], we provide the first nationwide population-based description of
bacterial meningitis and pneumococcal meningitis trends in Burkina Faso—one of the few
African countries to successfully implement case-based surveillance across the entire country.
We describe nationwide case-based meningitis surveillance data from 2011 to 2013, prior to
the introduction of PCV13 and in the setting of widespread use of Hib vaccine and
MenAfriVac.
Methods
National surveillance system
Burkina Faso’s nationwide bacterial meningitis surveillance system collects case-level demo-
graphic and clinical information, as well as results of cerebrospinal fluid (CSF) examination
Bacterial Meningitis in Burkina Faso before PCV13
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and laboratory testing, using Integrated Disease Surveillance and Response (IDSR) [4, 15]
instruments in all 63 districts. World Health Organization (WHO) case-based surveillance
guidelines for the African region [16] were revised in 2015 by the MenAfriNet Consortium
based upon the Burkina Faso Ministry of Health experience with successful implementation of
nationwide case-based meningitis surveillance.
Case identification
Cases were classified based upon WHO case definitions [17]. A case of suspected meningitis is
defined as sudden onset of fever38.5˚C with one of the following signs: neck stiffness, altered
consciousness, or other meningeal signs (including flaccid neck, bulging fontanel, or convul-
sions in young children). Probable bacterial meningitis is a suspected case with turbid, cloudy,
purulent, or xanthrochromic CSF; or presence of Gram negative diplococci, Gram positive
diplococci, or Gram negative bacilli on microscopic examination of CSF; or a CSF white cell
count>10/mm3. A confirmed case of meningitis is a suspected or probable case with S. pneu-
moniae, N. meningitidis, or H. influenzae isolated from CSF by culture or detected in CSF by
real-time polymerase chain reaction (rt-PCR) or latex agglutination.
Laboratory methods
CSF specimens are transported from healthcare facilities to district laboratories, which con-
duct preliminary lab testing such as cytology, Gram stain, and latex agglutination (Pastorex,
Bio-Rad). The remaining CSF is inoculated in trans-isolate media when available (stored at
room temperature) and also aliquoted into a cryotube (stored at -20˚C) for transportation to
one of five national reference laboratories for culture and rt-PCR testing.
Once a CSF specimen reaches a reference laboratory, it is visually observed for turbidity
and plated on chocolate agar. Plates are incubated at 35–37˚C with 5% CO2 and examined up
to 72 hours. Genomic DNA is extracted from 200 μl of CSF or cultures using the Qiagen DNA
Mini kit (Qiagen, Valencia, CA, USA) following an initial bacterial lysis step with lysozyme
(Sigma, USA) and mutanolysin (Sigma, USA) as previously described [18]. rt-PCR is used to
identify S. pneumoniae through targeting the lytA gene using primers and probes described by
Carvalho et al (2007) [18]. Similarly, the sodC and hpd3 genes are targeted for N. meningitidis
and H. influenzae, respectively [19]. DNA with equivocal values is diluted four-fold and ten-
fold and retested.
Serotyping of S. pneumoniae positive samples was performed using a series of seven sequen-
tial triplex rt-PCR assays targeting 37 pneumococcal serotypes [20; http://www.cdc.gov/
streplab/pcr.html]. Samples with Ct values of30 that were non-typeable by rt-PCR were fur-
ther analyzed by conventional multiplex PCR serotyping, which can detect an additional 33
serotypes [21; http://www.cdc.gov/streplab/pcr.html]. If samples were lytA-positive and sero-
type-negative both on rt-PCR and conventional PCR, they were classified as non-typeable S.
pneumoniae.
Statistical methods
We analyzed national meningitis surveillance data from January 1, 2011 to December 31,
2013. By December 31, 2013 (two months after PCV13 introduction), 31.1% of children aged
0–11 months had received one dose and 8.7% two doses of PCV13. Given that no children had
received the full 3-dose series by the end of 2013 and approximately two weeks are needed to
mount an effective immune response, data through December 31, 2013 was included in this
pre-PCV13 analysis. Residents of countries outside of Burkina Faso were excluded from
analyses.
Bacterial Meningitis in Burkina Faso before PCV13
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All cases were categorized according to their date of specimen collection. Pneumococcal
meningitis cases were categorized as either being caused by PCV13-associated serotypes (1, 3,
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, or 23F) or non-PCV13-associated serotypes. Annual
incidence rates (cases per 100,000 persons) were calculated using age-stratified population esti-
mates obtained from the Institut National de la Statistique et de la Démographie census. Dis-
tricts that did not report case-based meningitis surveillance data were excluded from the
incidence calculation denominator for that year. For suspected and probable bacterial menin-
gitis cases, crude incidence rates were reported. For laboratory-confirmed cases, annual inci-
dence was adjusted for the age-stratified proportion of cases with CSF tested at a national
laboratory, where culture and rt-PCR were performed. Within each age strata (<1 years, 1–4
years, 5–9 years, 10–14 years, and15 years), the number of cases confirmed by culture or rt-
PCR for a specific pathogen was divided by the number of cases with CSF tested via culture or
rt-PCR at a national laboratory; this proportion was then applied to cases lacking any test
results within that age strata. We calculated the positivity of each diagnostic test among total
cases confirmed as S. pneumoniae by any method, as well as sensitivity among the subset of
culture-positive cases. SAS version 9.3 was used for analyses.
Study approval
This analysis of surveillance data was approved by Burkina Faso Ministry of Health ethical
committee and was determined not to require Centers for Disease Control and Prevention
Institutional Review Board review.
Results
Data completeness and quality
The numbers of districts submitting data and specimens are shown in Table 1. CSF was col-
lected from a majority (97%) of reported suspected meningitis cases; 90% of CSF specimens
were tested by Gram stain at a district laboratory and 46% were subsequently tested at a
national reference laboratory (Fig 1, S1 Table). Twenty-four percent of CSFs were tested by
latex agglutination, 25% by culture, and 36% by rt-PCR.
National meningitis surveillance data
Over the three years of surveillance, 12,169 cases of suspected meningitis and 1,344 deaths
(11%) (Table 2) were reported, corresponding to an average annual incidence of 24.7 sus-
pected meningitis cases per 100,000 population (Table 3). The elevated number of suspected
cases in 2012 was due to a nationwide outbreak of serogroup W meningococcal meningitis
(Fig 2) [22]. Overall, 10,036 (82%) suspected cases occurred during meningitis season (epide-
miologic weeks 1–24). A fifth of suspected cases (20%, n = 2,384) occurred among children
aged<1 year, and nearly half (48%, n = 5,799) occurred in children under 5 years of age
(Table 2). Few cases were reported in infants aged<1 month (n = 15) or persons aged65
years (n = 149); the epidemiology in these two groups is described in S2 Table.
Fifty-four percent (n = 6,592) of all suspected cases met the probable case definition
(Table 2, Fig 2), for an average annual incidence of 13.1 (Table 3). Among suspected cases,
2,858 (23%) were laboratory-confirmed via latex, culture, or rt-PCR as either H. influenzae
(2%), N. meningitidis (44%), or S. pneumoniae (53%) (Table 2). All H. influenzae cases were
serotype b; N. meningitidis serogroups are reported in a footnote of Table 2.
In 2011, 2012, and 2013, relative proportions of laboratory-confirmed bacterial meningitis
cases that were caused by S. pneumoniae (75%, 36%, 60%) and N. meningitidis (22%, 63%,
Bacterial Meningitis in Burkina Faso before PCV13
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37%, respectively) varied, reflecting the meningococcal outbreak in 2012, while those due to H.
influenzae were rare (1–3%) (Table 2). S. pneumoniae had the highest CFR (23%), as compared
to N. meningitidis (9%) and H. influenzae (7%). Overall, S. pneumoniae caused 76% of all
deaths due to laboratory-confirmed bacterial meningitis. The average annual adjusted inci-
dence for S. pneumoniae, N. meningitidis, and H. influenzae, respectively, were 5.6, 4.8, and 0.2
per 100,000 among all ages (Table 3) and 26.9, 10.8, and 2.2 per 100,000 among children aged
<1 year.
Of the 1,528 confirmed pneumococcal meningitis cases reported in 2011–2013, 276 (18%)
occurred among children aged<1 year, and 478 (31%) occurred in children under 5 years of
age. Median age was 9 years (interquartile range: 2–16, range: 0–90). Adjusted average annual
incidence was highest among children aged<1 year (26.9 per 100,000, Table 3). CFR was high-
est among infants and adults: 32% in children aged<1 year, 15% in children aged 1–4 years,
21% in persons aged 5–29 years, and 30% in persons aged30 years. While the proportion of
persons aged<1 year, 1–4 years, 5–29 years, or30 years who recovered were 64%, 75%, 69%,
and 66%, respectively, 12%, 14%, 16%, and 13% were recorded as ‘on treatment’ and have an
unknown final outcome, and 0.0–0.6% in each age group left against medical advice.
Pneumococcal diagnostic test results
The ability of latex, culture, and rt-PCR tests to detect S. pneumoniae varied (Table 4). Overall,
642 (84.7%) of 758 laboratory-confirmed (using any of the three diagnostic methods) pneumo-
coccal meningitis cases tested using latex agglutination were positive for S. pneumoniae, and
217 (41.1%) of 528 tested by culture grew S. pneumoniae. The majority of pneumococcal men-
ingitis cases were confirmed using rt-PCR: 1,210 (96.3%) of 1,256 pneumococcal cases tested
by rt-PCR were positive for S. pneumoniae. Using culture as the gold standard, the sensitivities
Table 1. National meningitis data quality and completeness indicators, Burkina Faso, 2011–2013.
2011 2012 2013 Total
N (%) N (%) N (%) N (%)
Districts submitting case-based surveillance data 57/63 (90) 63/63 (100) 63/63 (100) 63/63 (100)
Districts submitting CSF specimens 57/63 (90) 63/63 (100) 63/63 (100) 63/63 (100)
Suspected meningitis cases with a LPa 2,766 (97) 6,302 (97) 2,758 (97) 11,826 (97)
CSFs assessed for appearance 2,417 (87) 5,723 (91) 2,585 (94) 10,725 (91)
CSFs with a Gram stainb 2,508 (91) 5,626 (89) 2,460 (89) 10,594 (90)
CSFs tested by cytology 1217 (44) 2,473 (39) 1,271 (46) 4,961 (42)
CSFs tested at a national laboratoryc,d 1,242 (45) 2,379 (38) 1,836 (67) 5,457 (46)
CSFs tested by latex 1,146 (41) 1,205 (19) 513 (19) 2,864 (24)
CSFs tested by culture 722 (26) 1,552 (25) 637 (23) 2,911 (25)
CSFs cultured but found to be contaminatede 190/722 (26) 275/1,552 (18) 107/637 (17) 572/2,911 (20)
CSFs tested by rt-PCR 1,133 (41) 1,396 (22) 1,704 (62) 4,233 (36)
Abbreviations: CSF, cerebrospinal fluid; LP, lumbar puncture; rt-PCR, real-time polymerase chain reaction.
a 1,166 (10%) of CSFs were tested by latex only, 742 (6%) by culture only, 2,017 (17%) by rt-PCR only, 482 (4%) by latex and culture, 529 (4%) by latex and
rt-PCR, 1,000 (8%) by culture and rt-PCR, and 687 (6%) by all three methods. 5,203 (44%) were not tested by any of the three methods.
b Possible reasons why an LP may not reach a district laboratory for gram staining: difficulty with specimen transport, geographic inaccessibility of certain
health centers, insufficient transport media
c Defined as being tested by culture and/or rt-PCR
d Possible reasons why an LP may not reach a national reference laboratory: insufficient transport media, insufficient quantity of CSF that was entirely used
for Gram staining and cytology.
e 447 (78%) of CSFs cultured but found to be contaminated were also tested by rt-PCR.
doi:10.1371/journal.pone.0166384.t001
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of latex agglutination and rt-PCR were 90.1% and 95.5%, respectively. Although testing prac-
tices varied by year, sensitivity of each of the three testing methods remained consistent.
Pneumococcal serotype distribution
Of the 1,528 pneumococcal meningitis cases, 1,036 (68%) were serotyped (Table 5 and S4
Table). Eighteen percent (n = 272) of cases were only positive via latex agglutination, so could
not be serotyped; 220 culture- or rt-PCR-positive cases did not have a specimen or isolate
available for serotyping (107 from 2011, 53 from 2012, and 60 from 2013) due to lack of isolate
storage, inability to locate isolates, or insufficient DNA available for serotyping. Overall, 737
(71%) were PCV13-associated serotypes, 141 (14%) were non-PCV13-associated serotypes,
and 158 (15%) were non-typeable. The predominant serotypes by age group were serotypes 5
(15%), 6A/6B (13%) and 1 (12%) among children aged<1 year; serotypes 1 (23%) and 6A/6B
(11%) among ages 1–4 years; and serotypes 1 (57%) and 12F/12A/12B/44/46 (8%) in persons
aged5 years (Table 5). Among children aged<5 years, 66% of cases were due to PCV13-as-
sociated serotypes. Overall, serotype 1 was responsible for 63% of PCV13-associated cases.
Temporal trends
Epidemic curves of the various case definitions of meningitis and of pneumococcal meningitis
cases (all ages and those aged <5 years) by month of specimen collection are shown in Figs 2–
4. Monthly trends followed the seasonality of meningitis epidemics typically observed in the
meningitis belt. The marked peak of meningococcal meningitis cases during the serogroup W
Fig 1. Flow diagram of the national case-based meningitis surveillance system, Burkina Faso, 2011–2013.
Abbreviation: rt-PCR, real-time polymerase chain reaction. *Specimens can be tested by multiple methods.
doi:10.1371/journal.pone.0166384.g001
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outbreak in 2012 is reflected in the increase in suspect, probable, and lab-confirmed cases in
Fig 2. In comparison, the seasonal peaks of pneumococcal meningitis cases showed less varia-
tion by year with the greatest activity in 2011 and successively smaller peaks in 2012 and 2013
(Figs 3 and 4). Seasonality of PCV13-associated cases and serotype 1 cases was similar to that
of overall pneumococcal meningitis.
Table 2. Cases reported through national meningitis surveillance by age group and etiology, Burkina Faso, 2011–2013.
2011 2012 2013 Total
N (%) N (%) N (%) N (%)
Suspected meningitis cases 2,841 6,499 2,829 12,169
Age groupa:
<1 year 591 (21) 1,219 (19) 574 (20) 2,384 (20)
1 year 194 (7) 555 (9) 244 (9) 993 (8)
2–4 years 473 (17) 1,383 (21) 566 (20) 2,422 (20)
5–9 years 504 (18) 1,323 (20) 516 (18) 2,343 (19)
10–14 years 402 (14) 826 (13) 333 (12) 1,561 (13)
15–29 years 366 (13) 655 (10) 341 (12) 1,362 (11)
30 years 298 (11) 508 (8) 240 (9) 1,046 (9)
Reported deaths 419 (15) 590 (9) 335 (12) 1,344 (11)
Probable bacterial meningitis cases 1,488 (52) 3,727 (57) 1,377 (49) 6,592 (54)
Laboratory-confirmed meningitis casesb 860 (30) 1,293 (20) 705 (25) 2,858 (23)
H. influenzaec 26 (3) 18 (1) 17 (2) 61 (2)
Age group
<5 years 16 (62) 13 (72) 14 (82) 43 (70)
5 years 10 (38) 5 (28) 3 (18) 18 (30)
Reported deaths 2 (8) 0 (0) 2 (12) 4 (7)
N. meningitidisd 192 (22) 813 (63) 264 (37) 1,269 (44)
Age groupe
<5 years 50 (26) 296 (36) 85 (32) 431 (34)
5 years 141 (74) 515 (64) 179 (68) 835 (66)
Reported deaths 21 (11) 62 (8) 28 (11) 111 (9)
S. pneumoniae 642 (75) 462 (36) 424 (60) 1,528 (53)
Age group:
<1 year 104 (16) 89 (19) 83 (20) 276 (18)
1 year 19 (3) 25 (5) 21 (5) 65 (4)
2–4 years 54 (8) 46 (10) 37 (9) 137 (9)
5–9 years 134 (21) 97 (21) 81 (19) 312 (20)
10–14 years 125 (20) 81 (18) 81 (19) 287 (19)
15–29 years 114 (18) 68 (15) 71 (17) 253 (17)
30 years 92 (14) 56 (12) 50 (12) 198 (13)
Reported deaths 179 (28) 94 (20) 84 (20) 357 (23)
a 58 cases missing age
b A confirmed case of meningitis is a suspected or probable case with S. pneumoniae, N. meningitidis, or H. influenzae isolated from CSF by culture or
detected in cerebrospinal fluid by real-time polymerase chain reaction or latex.
c All H. influenzae cases detected in 2011–2013 were serotype b.
d Serogroup was confirmed via culture or rt-PCR for 957 (75%) of 1,269 N. meningitidis cases: 751 (78%) were serogroup W, 204 (21%) were serogroup X,
1 (0.1%) was serogroup A, and 1 (0.1%) was serogroup Y.
e 3 N. meningitidis cases missing age.
doi:10.1371/journal.pone.0166384.t002
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Discussion
We report the first nationwide population-based description of bacterial meningitis, and spe-
cifically pneumococcal meningitis, in Burkina Faso following widespread use of Hib and ser-
ogroup A meningococcal conjugate vaccines. Pneumococcal meningitis was responsible for
the majority (53%) of laboratory-confirmed bacterial meningitis cases overall, and was charac-
terized by a higher case fatality (23%) than N. meningitidis (9%) and H. influenzae (7%). A
third of pneumococcal meningitis cases in Burkina Faso were in children aged<5 years, with
highest morbidity and mortality among children aged<1 year. Overall, serotype 1 was respon-
sible for 63% of all PCV13-associated infections and the proportion of pneumococcal infec-
tions due to serotype 1 increased with age. Pneumococcal meningitis demonstrated a
seasonality typically associated with meningococcal meningitis, with 75% to 97% of cases
occurring during meningitis season each year.
In this study, S. pneumoniae was responsible for the majority of laboratory-confirmed bac-
terial meningitis during non-meningococcal epidemic years– 2 of the 3 years we evaluated.
Most previous studies in Burkina Faso present data collected prior to the mass MenAfriVac
vaccination campaign in 2010. Therefore, with serogroup A meningococcus still circulating,
these earlier studies reported a relatively low proportion of bacterial meningitis that was pneu-
mococcal, ranging from 14% to 44% [5–7, 23].
These results of national meningitis surveillance—a high case fatality of pneumococcal
meningitis, a predominance of serotype 1 after the first five years of life, and seasonality—reaf-
firmed findings of previous pneumococcal meningitis studies that were based on surveillance
Table 3. Annual incidence (cases per 100,000 persons) of suspected, probable, and confirmed meningitis, Burkina Faso, 2011–2013.
2011 2012 2013 Average
Suspected meningitis casesa 19.0 38.7 16.3 24.7
Probable bacterial meningitis casesa 9.2 22.2 7.9 13.1
Laboratory-confirmed meningitis casesb,c 9.4 16.5 5.7 10.5
H. influenzae 0.3 0.2 0.1 0.2
Age group
<5 years 1.0 0.8 0.6 0.8
5 years 0.1 0.1 0.0 0.1
N. meningitidis 2.1 10.1 2.1 4.8
Age group
<5 years 3.3 20.6 3.6 9.2
5 years 1.7 7.7 1.8 3.7
S. pneumoniae 7.1 6.2 3.5 5.6
Age group
<1 years 31.3 32.9 16.5 26.9
1–4 years 6.6 6.5 3.1 5.4
5–9 years 9.2 8.1 4.0 7.1
10–14 years 9.7 7.3 4.9 7.3
15 years 4.0 3.1 2.0 3.0
a Crude incidence
b A confirmed case of meningitis is a suspected or probable case with S. pneumoniae, N. meningitidis, or H. influenzae isolated from cerebrospinal fluid
(CSF) by culture or detected in CSF by real-time polymerase chain reaction or latex.
c Incidence adjusted for the proportion of cases with CSF tested at a national laboratory.
Note: Incidences in the subset of high-reporting districts that provided case-based data for at least 65% of aggregately-reported cases are reported in S3
Table.
doi:10.1371/journal.pone.0166384.t003
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Fig 2. Epidemic curve of all suspected, probable, and confirmed meningitis cases by month, Burkina Faso, 2011–2013.
doi:10.1371/journal.pone.0166384.g002
Table 4. S. pneumoniae diagnostic test results among confirmeda pneumococcal meningitis cases, Burkina Faso, 2011–2013.
Diagnostic testing method 2011 2012 2013 Total
No. positive for S. pneumoniae using method(s) (%)
Latex only 151 (23.5) 83 (18.0) 38 (9.0) 272 (17.8)
Culture only 8 (1.3) 18 (3.9) 1 (0.2) 27 (1.8)
rt-PCR only 216 (33.6) 257 (55.6) 305 (71.9) 778 (50.9)
Latex and culture only 9 (1.4) 8 (1.7) 2 (0.5) 19 (1.2)
Latex and rt-PCR only 158 (24.6) 62 (13.4) 41 (9.7) 261 (17.1)
Culture and rt-PCR 34 (5.3) 14 (3.0) 33 (7.8) 81 (5.3)
Latex, culture and rt-PCR 66 (10.3) 20 (4.3) 4 (0.9) 90 (5.9)
No. positive / No. of confirmeda cases tested using method (%)
Latex 384/453 (84.8) 173/201 (86.1) 85/104 (81.7) 642/758 (84.7)
Culture 117/271 (43.2) 60/148 (40.5) 40/109 (36.7) 217/528 (41.1)
rt-PCR 474/504 (94.0) 353/360 (98.1) 383/392 (97.7) 1,210/1,256 (96.3)
Sensitivity using culture as the gold standard
No. positive / No. of culture-positive cases tested using method (%)
Latex 75/79 (94.9) 28/34 (82.4) 6/8 (75.0) 109/121 (90.1)
rt-PCR 100/105 (95.2) 34/37 (91.9) 37/37 (100.0) 171/179 (95.5)
Total positive for S. pneumoniae 642 462 424 1,528
Abbreviations: rt-PCR, real-time polymerase chain reaction.
a S. pneumoniae isolated from cerebrospinal fluid (CSF) by culture or detected in CSF by rt-PCR or latex. Not all specimens were tested via all three
methods.
doi:10.1371/journal.pone.0166384.t004
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in 3 to 4 of the 63 districts in Burkina Faso [5–7, 9]. However, our adjusted average annual
pneumococcal meningitis incidence of 5.6 cases per 100,000 in this national surveillance sys-
tem was lower than many previously reported in the region (range: 9 to 17) [5–7, 24], although
we found children aged<1 year had an incidence nearly nine times that observed among
other ages, which is consistent with previous reports [7, 8]. Our reported pneumococcal men-
ingitis incidence in children aged <5 years (10.1 per 100,000) was also lower than the esti-
mated incidence modelled by O’Brien et al for the Africa region in 2000 (38 per 100,000,
Table 5. Distribution of pneumococcal serotypes by age, Burkina Faso, 2011–2013.
Pneumococcal serotype <1 year,N (%) 1–4 years,N (%) 5 years,N (%) Total,N (%)
PCV13-associated 124 (65) 83 (67) 530 (74) 737 (71)
1 22 (12) 28 (23) 414 (57) 464 (45)
3 0 (0) 1 (1) 4 (1) 5 (0.5)
4 2 (1) 1 (1) 7 (1) 10 (1)
5 28 (15) 8 (6) 35 (5) 71 (7)
6A/6B 24 (13) 14 (11) 8 (1) 46 (4)
7F/7A 4 (2) 4 (3) 8 (1) 16 (2)
9V/9A 2 (1) 0 (0) 1 (0.1) 3 (0.3)
14 14 (7) 6 (5) 14 (2) 34 (3)
18C/18F/18B/18A 8 (4) 4 (3) 8 (1) 20 (2)
19A 4 (2) 1 (1) 4 (1) 9 (1)
19F 2 (1) 5 (4) 4 (1) 11 (1)
23F 14 (7) 11 (9) 23 (3) 48 (5)
Non-PCV13-associated 37 (19) 15 (12) 89 (12) 141 (14)
2 13 (7) 0 (0) 4 (1) 17 (2)
7C/7B/40 0 (0) 0 (0) 0 (0) 0 (0)
8 0 (0) 0 (0) 2 (0.3) 2 (0.2)
9N/9L 2 (1) 1 (1) 1 (0.2) 4 (0.4)
10F/10C/33C 1 (1) 0 (0) 0 (0) 1 (0.1)
11A/11D 0 (0) 0 (0) 1 (0.1) 1 (0.1)
12F/12A/12B/44/46 18 (9) 7 (6) 57 (8) 82 (8)
13 0 (0) 0 (0) 1 (0.1) 1 (0.1)
15B/15C 0 (0) 0 (0) 5 (1) 5 (0.5)
16F 1 (1) 0 (0) 3 (0.4) 4 (0.4)
21 0 (0) 2 (2) 0 (0) 2 (0.2)
22F/22A 0 (0) 0 (0) 2 (0.3) 2 (0.2)
23B 0 (0) 1 (1) 0 (0) 1 (0.1)
24F/24A/24B 0 (0) 1 (1) 1 (0.1) 2 (0.2)
25F/25A/38 0 (0) 3 (2) 10 (1) 13 (1)
33F/33A/37 1 (1) 0 (0) 0 (0) 1 (0.1)
34 0 (0) 0 (0) 1 (0.1) 1 (0.1)
35B 1 (1) 0 (0) 1 (0.1) 2 (0.2)
Non-typeable 30 (16) 26 (21) 102 (14) 158 (15)
Total serotyped 191 (69) 124 (61) 721 (69) 1,036 (68)
Missing serotypea 85 (31) 78 (39) 329 (31) 492 (32)
Total 276 202 1,050 1,528
a 272 cases were positive only via latex agglutination and could not be serotyped: 151 from 2011, 83 from 2012, and 38 from 2013. Serotype results were
unavailable for 220 culture- and/or rt-PCR-positive cases: 107 from 2011, 53 from 2012, and 60 from 2013.
doi:10.1371/journal.pone.0166384.t005
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uncertainty range: 11–48) [1]. Our reported incidences may be lower for a number of reasons:
1) while previous studies report sentinel surveillance incidences or use sentinel incidences to
estimate national incidences, we report full nationwide incidence; 2) this analysis describes
cases detected through routine clinical care and reported through routine channels as part of
nationwide passive surveillance, as opposed to active, sentinel surveillance supported by spe-
cial research studies and additional infrastructure; some cases were likely undiagnosed or
unreported; 3) sentinel surveillance incidence rates based on persons seeking care at a referral
hospital may be inaccurate if persons not included in the surveillance catchment area (denom-
inator) seek care for meningitis and are included, or if cases seek care outside the catchment
area; 4) sentinel surveillance sites or special research studies may be purposely placed in areas
with high meningitis incidence or urban areas with higher population density and therefore
higher potential for transmission; and 5) this analysis uses recent data from 2011 to 2013, per-
haps reflecting true decreases in incidence since previous studies were completed. Although
this national surveillance system likely results in underreporting, the methods used here are
more sustainable for countries in the region and enable analysis of disease trends.
We reported a CFR of 23% for pneumococcal meningitis in cases of all ages, lower than all
previously-reported estimates (40%-47%) in the region [5–8, 23, 24]. Across all reports the
mortality was highest among children aged<1 year. Our CFR may be lower due to incomplete
capture of outcomes nationwide; many patients were reported as being ‘on treatment’ and
their final outcome was not subsequently documented by national surveillance. However,
Fig 3. Epidemic curve of confirmed* pneumococcal meningitis cases, serotyped pneumococcal meningitis cases, PCV13-associated
pneumococcal meningitis cases, and serotype 1 pneumococcal meningitis cases by month, Burkina Faso, 2011–2013. *S. pneumoniae isolated
from cerebrospinal fluid (CSF) by culture or detected in CSF by real-time polymerase chain reaction or latex.
doi:10.1371/journal.pone.0166384.g003
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incomplete mortality reporting would equally occur with all pathogens, and S. pneumoniae
was still responsible for 76% of bacterial meningitis deaths in Burkina Faso. This highlights the
high comparative burden of pneumococcal meningitis mortality, which has been noted previ-
ously [5–7]. We could not assess the full burden or serotype distribution of pneumococcal
infections as Burkina Faso does not conduct surveillance for other pneumococcal syndromes
such as pneumonia or sepsis. Also, there was no available data on disease-related sequelae
other than deaths, which can affect as many as half of children with pneumococcal meningitis
[25–27].
Serotype 1 continues to predominate in this region, causing 45% of pneumococcal menin-
gitis in all age groups and 57% of cases aged5 years. This overall proportion is nearly identi-
cal to that reported previously [6, 9, 28]. In young children, serotypes 1, 5, and 6A/6B caused
40% of serotyped cases; we found fewer cases caused by serotypes 2, 3, 14, 2, and 18 than
reported previously [7, 8, 29]. Among children aged<5 years, 66% of disease was covered by
serotypes included in PCV13, consistent with estimates (53–67%) in previous reports [7, 9],
indicating that PCV13 introduction has potential for substantial impact on disease burden
among children. PCV13-associated serotypes caused 74% of pneumococcal meningitis in per-
sons aged5 years, indicating that widespread use of PCV13 among infants could have a
major impact on meningitis among older age groups through indirect protection. However,
given that most cases due to PCV13-associated serotypes were in fact caused by serotype 1, a
Fig 4. Epidemic curve of confirmed* pneumococcal meningitis cases, serotyped pneumococcal meningitis cases, PCV13-associated
pneumococcal meningitis cases, and serotype 1 pneumococcal meningitis cases among children aged <5 years, by month, Burkina Faso, 2011–
2013. *S. pneumoniae isolated from cerebrospinal fluid (CSF) by culture or detected in CSF by real-time polymerase chain reaction or latex.
doi:10.1371/journal.pone.0166384.g004
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serotype rarely found in colonization studies [30], the effect of PCV13 on herd immunity
among non-vaccinated persons in Burkina Faso remains to be seen. We found a high propor-
tion (15%) of non-typeables, despite using both rt-PCR and conventional PCR methods to
serotype all pneumococcal isolates and specimens. This is consistent with previous studies in
the region [9], and may reflect circulating serotypes that are not covered by existing methods.
The national case-based meningitis surveillance system in Burkina Faso is continually
improving. All districts are now submitting CSF specimens and the proportion of CSFs tested
by culture or rt-PCR at a national laboratory increased from 45% in 2011 to 67% by 2013. We
adjusted incidence rates to partially account for this under-testing. However, challenges
remain, particularly with increasing timely specimen transport to national laboratories and
ensuring that the proper transport media and containers are available where and when they
are needed. As case ascertainment and outcome reporting continue to improve, this national
surveillance system produces robust nationwide estimates that can be considered a lower
bound for estimates of incidence and CFR.
In our study, the positivity of culture for diagnosis of pneumococcal meningitis was low
(41%). CSF culture is considered the gold standard for diagnosis of bacterial meningitis and is
positive in 80–90% of patients with acute community-acquired bacterial meningitis before the
start of treatment [31]. Our low culture positivity is likely due to a number of reasons including
1) prior antibiotic use; 2) delayed culture of CSF specimen due to lack of culture capacity at
regional laboratories; 3) lack of availability of blood agar plates for optimal recovery of pneu-
mococci, and 4) a high proportion of contaminated cultures (20%). The strengthening of the
national bacterial meningitis surveillance system to include capacity for rt-PCR testing at
national laboratories significantly increased pneumococcal meningitis case confirmation and
also provided a platform for pneumococcal serotyping.
This analysis is the first nationwide population-based report of pneumococcal meningitis
epidemiology in Burkina Faso and the first to include routine serotyping of pneumococcal
specimens throughout the entire country. Serotyping all pneumococcal meningitis specimens
as part of the national surveillance system is essential to understanding the epidemiology and
evaluating pneumococcal vaccination efforts. This data analysis serves as a baseline against
which PCV13 impact can be measured. Introduction of PCV13 should decrease the burden of
pneumococcal meningitis, as most cases were due to vaccine-associated serotypes. Addition-
ally, widespread use of PCV13 among infants could have a major impact on pneumococcal dis-
ease among older children and adults if the infant routine immunization program induces
indirect protection against serotype 1 and other PCV13-associated serotypes.
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